ProQR shares are trading higher after the company, along with Eli Lilly, announced the expansion of their licensing and collaboration agreement of new genetic medicines. ProQR will receive an upfront payment of $75 million, plus an equity investment.
Benzinga Newsdesk - Dec 22, 2022, 9:03AM